St. Jude Medical's Neurostimulation System in Japan | St Jude Medical, Inc.
LinkedIn Login

Connect healthcare products, companies and hospitals with your LinkedIn network.

Facebook Login

Interact with your Facebook network around healthcare products, companies and hospitals.

Login With Facebook
MedicExchange Login

Enjoy Premium Access as a MedicExchange Member.

       Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Facebook Twitter Linkedin
Facebook: MedicExchange
Twitter: MedicExchange
Healthcare Company News St Jude Medical, Inc. St. Jude Medical's Neurostimulation System in Japan

St. Jude Medical's Neurostimulation System in Japan

Company News - St Jude Medical, Inc.

St. Jude Medical 's genesis spinal cord stimulation system aids patients suffering from chronic pain.

St. Jude Medical , Inc. announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the Genesis spinal cord stimulation system for the management of chronic pain.

Spinal cord stimulators are small implanted devices that are used for managing chronic pain of the back, arms and legs, including pain associated with back surgeries that have failed. Spinal cord stimulators - also known as neurostimulators -- deliver mild electrical pulses to leads placed in the epidural space to interrupt or mask the transmission of pain signals to the brain.

"The launch of the Genesis system in Japan is a significant step in our continued international growth," said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "We are excited to introduce our technology in Japan and to be able to provide a new option for physicians and patients that will help them manage the severest forms of chronic pain."

The Genesis neurostimulator features:

  • Compact size (28 cc) which provides physicians flexibility in placement options
  • Constant current stimulation for consistent delivery of therapy
  • Maximum power output of 25.5mA (~12V) to address high energy needs

Neurostimulation therapy is unique in that it provides patients with the opportunity to experience the therapy before moving forward with the permanent implant. Typically the patient undergoes a minimally invasive outpatient procedure to determine if the therapy provides adequate relief. Following this short evaluation period, the physician and patient can decide to proceed with a permanent implant.

The Genesis neurostimulator also allows patients the freedom to adjust their therapy as needed within parameters set by physicians. Each patient has a programmer that turns the system on and off and allows them to select from 24 different patient-specific customized stimulation programs, enabling them to manage their pain on a daily basis.

The launch of the Genesis neurostimulation system in Japan adds to the portfolio of products available to physicians from St. Jude Medical Japan. Others include:

  • Cardiac Rhythm Management devices for the treatment of abnormal heart rhythms and heart failure (Zephyr pacemaker, Frontier II CRT-P, Current Implantable Cardioverter Defibrillator [ICD], Promote Cardiac Resynchronization Therapy Defibrillator [CRT-D], IsoFlex Pacing Leads, Tendril ST Optim Pacing Lead, Durata Defibrillation Lead, and others)
  • Products within the Atrial Fibrillation Division which aid physicians in accessing, diagnosing and treating cardiac arrhythmias (EnsiteTM 3D Cardiac Mapping System, Inquiry Diagnostic Catheter IBI Ablation Catheter, SwartzTM Braided Introducer, Agilis NxT Introducer, and others)
  • Cardiology products for the diagnoses and treatment of cardiovascular and valvular disease (SJM Regent Mechanical Heart Valve, SJM Rigid Saddle Ring, SJM TailorTM Ring+Band, Angio-Seal Evolution Vascular Closure Device, Signet Pro PTCA Balloon Catheter, PressureWire, Certus FFR Measurement System, and others)

Chronic pain is a largely under-treated and misunderstood condition that affects millions of patients worldwide. The World Health Organization, in conjunction with the International Association for the Study of Pain (IASP), reports that as many as one in five people suffers from moderate to severe chronic pain.

More than 60,000 patients in 35 countries have been implanted with St. Jude Medical neurostimulation systems. Patients can obtain more information about neurostimulation therapy at www.PowerOverYourPain.com.

Source: St. Jude Medical

You can discuss about St. Jude Medical and its products & services in the St. Jude Medical Company User Group